Breaking News Instant updates and real-time market news.

CFRX

ContraFect

$0.42

0.0075 (1.83%)

07:16
05/31/19
05/31
07:16
05/31/19
07:16

ContraFect announces exebacase data in antimicrobial agents published

ContraFect announced that an article will be published in the June edition of the peer-reviewed Antimicrobial Agents and Chemotherapy Journal of the American Society of Microbiology. Exebacase is a recombinantly-produced lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or BSIs, also known as bacteremia. The paper describes a series of in vitro studies of pharmacodynamic parameters of exebacase against Staph aureus, including the postantibiotic effect, or PAE, postantibiotic sub-minimum inhibitory concentration, or MIC, effect and sub-MIC effect. The study examined how sub-MIC exebacase exposures affect bacterial growth and extend its antimicrobial activity against 14 different Staphylococcus aureus strains tested in human serum. The findings demonstrated that sub-MIC exposures to exebacase resulted in aberrant changes in bacterial cell wall structure and inhibition of virulence phenotypes, including biofilm formation. In an animal model of Staph aureus infection, PAE resulted in bacterial growth delays of 19 hours and extended growth delays by 6 hours in the presence of daptomycin. These data suggest that sub-MIC concentrations of exebacase during therapeutic use in addition to standard of care antibiotics, may contribute to efficacy via sustained reductions in bacterial fitness and virulence.

CFRX ContraFect
$0.42

0.0075 (1.83%)

06/28/18
JANY
06/28/18
INITIATION
JANY
Buy
ContraFect initiated with a Buy at Janney Montgomery Scott
06/28/18
06/28/18
INITIATION
Target $4

Buy
Janney Montgomery Scott starts ContraFect at Buy with $4 fair value estimate
As previously reported, Janney Montgomery Scott analyst Esther Hong initiated ContraFect with a Buy rating and $4 fair value estimate, stating that its lysin platform has the potential to fill an urgent unmet need in the treatment of serious multidrug resistant pathogens. The company's lead program, CF-301, has shown "compelling" preclinical data, said Hong, who sees the upcoming Phase 2 data for CF-301 as an inflection point for investor interest.Target $4.
07/10/18
LTCO
07/10/18
INITIATION
Target $3
LTCO
Buy
ContraFect initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started ContraFect with a Buy rating and $3 price target. The analyst expects positive endocarditis data in Q4.
09/06/18
PIPR
09/06/18
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight as ContraFect completes study enrollment
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on ContraFect, noting the company has completed its Phase II randomization of 115 Staphylococcus aureus bacteremia patients to a single IV infusion of exebacase or placebo on top of standard-of-care antibiotics, a trial that is designed to show superiority on the primary endpoint of clinical response at day 14. Tenthoff expects to see top-line data from the study in Q4 of this year.

TODAY'S FREE FLY STORIES

TRLFF

True Leaf Medicine

$0.00

(0.00%)

, NXTTF

Namaste Technologies

$0.00

(0.00%)

07:27
06/24/19
06/24
07:27
06/24/19
07:27
Hot Stocks
True Leaf Medicine announces supply agreement with Namaste Technologies »

True Leaf Brands (TRLFF)…

TRLFF

True Leaf Medicine

$0.00

(0.00%)

NXTTF

Namaste Technologies

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARLP

Alliance Resource Partners

$16.96

-0.12 (-0.70%)

07:27
06/24/19
06/24
07:27
06/24/19
07:27
Hot Stocks
Alliance Resource Partners to acquire $145M of Permian Basin interests »

Alliance Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNET

RigNet

$8.64

0.22 (2.61%)

, IMASY

Inmarsat

$0.00

(0.00%)

07:25
06/24/19
06/24
07:25
06/24/19
07:25
Hot Stocks
RigNet announces settlement of Inmarsat arbitration »

RigNet (RNET) announced…

RNET

RigNet

$8.64

0.22 (2.61%)

IMASY

Inmarsat

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$76.12

-0.82 (-1.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Upgrade
Fortinet rating change  »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

POST

Post Holdings

$104.28

0.075 (0.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Post Holdings narrows FY19 adjusted EBITDA view $1.2B-$1.22B from $1.2B-$1.24B »

Post Holdings provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMUX

Immunic

$9.71

0.04 (0.41%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Immunic to present unpublished IMU-838 data at GIIDS »

Immunic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

PSTI

Pluristem

$0.57

-0.0142 (-2.43%)

07:21
06/24/19
06/24
07:21
06/24/19
07:21
Hot Stocks
Pluristem appoints Yaky Yanay as sole CEO »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$6.57

-0.19 (-2.81%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Conference/Events
Pfenex management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Oct

INNT

Innovate Biopharmaceuticals

$1.23

-0.025 (-2.00%)

, CGIX

Cancer Genetics

$0.17

-0.0033 (-1.89%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Hot Stocks
Innovate Biopharmaceuticals appoints ED Sitar as CFO »

Innovate…

INNT

Innovate Biopharmaceuticals

$1.23

-0.025 (-2.00%)

CGIX

Cancer Genetics

$0.17

-0.0033 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$57.07

-0.54 (-0.94%)

07:18
06/24/19
06/24
07:18
06/24/19
07:18
Conference/Events
NuVasive management to meet with BTIG »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

07:15
06/24/19
06/24
07:15
06/24/19
07:15
General news
FX Update: The dollar has started the week on a soft footing »

FX Update: The dollar has…

DAN

Dana

$17.94

0.05 (0.28%)

07:14
06/24/19
06/24
07:14
06/24/19
07:14
Hot Stocks
Dana announces reduction of pension liabilities »

Dana announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRN

Materion

$67.06

-0.54 (-0.80%)

07:14
06/24/19
06/24
07:14
06/24/19
07:14
Conference/Events
Materion management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 25

    Sep

CGC

Canopy Growth

$40.20

-3.495 (-8.00%)

07:13
06/24/19
06/24
07:13
06/24/19
07:13
Hot Stocks
Canopy Growth adds substantial production capacity in Canada »

Canopy Growth is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$32.46

0.58 (1.82%)

07:12
06/24/19
06/24
07:12
06/24/19
07:12
Conference/Events
MPLX management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

MDR

McDermott

$8.35

0.14 (1.71%)

07:12
06/24/19
06/24
07:12
06/24/19
07:12
Hot Stocks
McDermott awarded large offshore EPCI contract from Saudi Aramco »

McDermott announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$29.98

0.2 (0.67%)

07:10
06/24/19
06/24
07:10
06/24/19
07:10
Hot Stocks
Axalta Coating announces Chairman Charlie Shaver resigns, Mark Garrett succeeds »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORV

Correvio

$2.27

-0.13 (-5.42%)

07:09
06/24/19
06/24
07:09
06/24/19
07:09
Hot Stocks
Correvio resubmits Brinavess NDA to FDA »

Correvio announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

07:07
06/24/19
06/24
07:07
06/24/19
07:07
Hot Stocks
Bristol-Myers: CheckMate -459 study did not reach pre-specified primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

, CELG

Celgene

$98.92

0.75 (0.76%)

07:05
06/24/19
06/24
07:05
06/24/19
07:05
Hot Stocks
Bristol-Myers plans Otezla sale to get FTC Celgene clearance »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

CELG

Celgene

$98.92

0.75 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

, CELG

Celgene

$98.92

0.75 (0.76%)

07:03
06/24/19
06/24
07:03
06/24/19
07:03
Hot Stocks
Breaking Hot Stocks news story on Bristol-Myers, Celgene »

Bristol-Myers plans…

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

CELG

Celgene

$98.92

0.75 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ATNX

Athenex

$17.95

-0.06 (-0.33%)

07:02
06/24/19
06/24
07:02
06/24/19
07:02
Hot Stocks
Athenex announces FDA allowance of IND application for PT01 »

Athenex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSLR

Vivint Solar

$7.27

-0.15 (-2.02%)

07:00
06/24/19
06/24
07:00
06/24/19
07:00
Hot Stocks
Vivint Solar closes $100M in financing to install over 55 megawatts of systems »

Vivint Solar announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 20

    Aug

  • 21

    Aug

TWNK

Hostess Brands

$13.89

0.065 (0.47%)

06:59
06/24/19
06/24
06:59
06/24/19
06:59
Upgrade
Hostess Brands rating change  »

Hostess Brands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$78.85

-0.79 (-0.99%)

06:57
06/24/19
06/24
06:57
06/24/19
06:57
Hot Stocks
Leidos awarded $49M HHS artificial intelligence contract »

Leidos has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.